Clinical Trials | December 15, 2022
Biocon initiates clinical study of Itolizumab for ulcerative colitis in India
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial
The use of procalcitonin testing for sepsis management is highest in the US
The IPO is a complete OFS by existing shareholder Helix Investment Holdings
Antibody levels remained above baseline six months after completion of a three-dose (Month 0-2-6) or a two-dose (Month 0-6) vaccination schedule
Phase-III trials were conducted for safety, and immunogenicity in around 3,100 subjects, in 14 trial sites across India (supported by BIRAC)
QS-21 in blockbuster Shingles vaccine, first vaccine approved for Malaria, promising RSV phase III candidate, and Covid-19 applications.
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
The receipt of this permission paves way for the launch of Dapagliflozin (Forxiga) tablets of 10 mg in India for the specified additional/expanded indication, subject to the receipt of related statutory approvals
The product is expected to be launched by Q4 FY23.
Subscribe To Our Newsletter & Stay Updated
